{
    "id": "62266c353a8413c65300008a",
    "question": "Can autophagy related lncRNAs be used for colorectal cancer prognosis?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to understand the relationship between autophagy and colorectal cancer, as well as the role of long non-coding RNAs (lncRNAs) in this context. Autophagy is a cellular process that can have both tumor-suppressive and tumor-promoting effects, depending on the context. In the case of colorectal cancer, autophagy can act as a mechanism to protect cancer cells from nutrient deprivation and stress, which can contribute to tumor growth and resistance to therapy. However, autophagy can also be inhibited in certain types of cancer, including colorectal cancer, which can make it a potential target for therapeutic intervention. LncRNAs are a class of non-coding RNAs that have been implicated in various cellular processes, including cell growth, differentiation, and apoptosis. Some lncRNAs have been shown to be involved in the regulation of autophagy, and their expression levels may be altered in colorectal cancer. Given this background, the question of whether autophagy-related lncRNAs can be used for colorectal cancer prognosis is an interesting one. Research has shown that certain lncRNAs are differentially expressed in colorectal cancer tissues compared to normal tissues, and these lncRNAs may play a role in the development and progression of the disease. Specifically, some studies have suggested that autophagy-related lncRNAs may be involved in the regulation of autophagy in colorectal cancer cells, and their expression levels may be correlated with clinical outcomes. Therefore, it is reasonable to conclude that autophagy-related lncRNAs may be used for colorectal cancer prognosis, as they may provide valuable biomarkers for predicting patient outcomes and guiding treatment decisions. Based on this reasoning, the correct answer is A. yes.\", \"answer_choice\": \"A\"}}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_6171",
            "title": "InternalMed_Harrison",
            "content": "The mechanisms that control the balance between enhancing survival versus leading to cell death are still not fully understood. Autophagy appears to play conflicting roles in the development and survival of cancer. Early in the carcinogenic process, it can act as a tumor suppressor by preventing the cell from accumulating abnormal proteins and organelles. However, in established tumors, it may serve as a mechanism of survival for cancer cells when they are stressed by damage such as from chemotherapy. Inhibition of this process can enhance the sensitivity of cancer cells to chemotherapy. Better understanding of the factors that control the survival-promoting versus death-inducing aspects of autophagy is required in order to know how to best manipulate it for therapeutic benefit."
        },
        {
            "id": "Surgery_Schwartz_2103",
            "title": "Surgery_Schwartz",
            "content": "to nutrient deprivation, or consti-tutive activation of autophagy in response to stress, can lead to cell death; thus, autophagy is sometimes referred to as a second form of programmed cell death. Autophagy plays an essential role during starvation, cellular differentiation, cell death, and aging. Autophagy is also involved in the elimination of cancer cells by triggering a nonapoptotic cell death program, which suggests a negative role in tumor development. Mouse models that are heterozygotes for the beclin 1 gene, an important gene for autophagy, have altered autophagic response and show a high incidence of spontaneous tumors, which establishes a role for autophagy in tumor suppression.21 This also suggests that mutations in other genes operating in this pathway may con-tribute to tumor formation through deregulation of autophagy. However, autophagy also acts as a stress response mechanism to protect cancer cells from low nutrient supply or therapeu-tic insults. Thus, in cancer,"
        },
        {
            "id": "InternalMed_Harrison_6154",
            "title": "InternalMed_Harrison",
            "content": "Epigenetic gene regulation can also occur via microRNAs or long non-coding RNAs (lncRNAs). MicroRNAs are short (average 22 nucleotides in length) RNA molecules that silence gene expression after transcription by binding and inhibiting the translation or promoting the degradation of mRNA transcripts. It is estimated that more than 1000 microRNAs are encoded in the human genome. Each tissue has a distinctive repertoire of microRNA expression, and this pattern is altered in specific ways in cancers. However, specific correlations between microRNA expression and tumor biology and clinical behavior are just now emerging. Therapies targeting microRNAs are not currently at hand but represent a novel area of treatment development. lncRNAs are longer than 200 nucleotides and compose the largest group of noncoding RNAs. Some of them have been shown to play important roles in gene regulation. The potential for altering these RNAs for therapeutic benefit is an area of active investigation,"
        },
        {
            "id": "Pathology_Robbins_231",
            "title": "Pathology_Robbins",
            "content": "Extensive autophagy is seen in ischemic injury and some types of myopathies. Polymorphisms in a gene involved in autophagy have been associated with inflammatory bowel disease, but the mechanistic link between autophagy and intestinal inflammation is not known. The role of autophagy in cancer is discussed in Chapter 6. Thus, a once little-appreciated survival pathway in cells may prove to have wide-ranging roles in human disease. http://ebooksmedicine.net Fig. 2.14 Autophagy. Cellular stresses, such as nutrient deprivation, activate autophagy genes, which initiate the formation of membrane-bound vesicles in which cellular organelles are sequestered. These vesicles fuse with lysosomes, in which the organelles are digested, and the products are used to provide nutrients for the cell. The same process can trigger apoptosis by mechanisms that are not well defined."
        },
        {
            "id": "Pathology_Robbins_1292",
            "title": "Pathology_Robbins",
            "content": "cells to survive hard times for long periods. Such cells are believed to be resistant to therapies that kill actively dividing cells, and could therefore be responsible for therapeutic failures. Thus, autophagy may be a tumor\u2019s friend or foe depending on how the signaling pathways that regulate it are \u201cwired\u201d in a given tumor."
        },
        {
            "id": "Surgery_Schwartz_2104",
            "title": "Surgery_Schwartz",
            "content": "formation through deregulation of autophagy. However, autophagy also acts as a stress response mechanism to protect cancer cells from low nutrient supply or therapeu-tic insults. Thus, in cancer, autophagy can have opposing and context-dependent roles, and interventions to both stimulate and inhibit autophagy have been proposed as possible antican-cer treatments. Studies on the molecular controls of autophagy are ongoing and are expected to generate novel therapeutic strategies. Chloroquin is an antimalarial drug that acts as an autophagic inhibitor by blocking the autophagosome and has been tested for its anticancer properties.Cancer InvasionA feature of malignant cells is their ability to invade the sur-rounding normal tissue. Tumors in which the malignant cells appear to lie exclusively above the basement membrane are referred to as in situ cancer, whereas tumors in which the malig-nant cells are demonstrated to breach the basement membrane, penetrating into surrounding stroma, are"
        },
        {
            "id": "Pathology_Robbins_23",
            "title": "Pathology_Robbins",
            "content": "A. Gene activation Ribonucleoprotein transcription complex Decoy lncRNAB. Gene suppression Gene suppression C. Promote chromatin modification Methylation, D. Assembly of protein complexes Fig. 1.4 Roles of long noncoding RNAs (lncRNAs). (A) Long noncoding RNAs (lncRNAs) can facilitate transcription factor binding and thus promote gene activation. (B) Conversely, lncRNAs can preemptively bind transcription factors and thus prevent gene transcription. (C) Histone and DNA modification by acetylases or methylases (or deacetylases and demethylases) may be directed by the binding of lncRNAs. (D) In other instances lncRNAs may act as scaffolding to stabilize secondary or tertiary structures and/or multisubunit complexes that influence general chromatin architecture or gene activity. (Adapted from Wang KC, Chang HY: Molecular mechanisms of long noncoding RNAs, Mol Cell 43:904, 2011.) a variety of mechanisms ("
        },
        {
            "id": "Pathology_Robbins_20",
            "title": "Pathology_Robbins",
            "content": "Taking advantage of the same pathway, small interfering RNAs (siRNAs) are short RNA sequences that can be introduced into cells. These serve as substrates for Dicer and interact with the RISC complex in a manner analogous to endogenous miRNAs. Synthetic siRNAs that can target specific mRNA species are therefore powerful laboratory tools to study gene function (so-called knockdown technology); they also are promising as therapeutic agents to silence pathogenic genes, e.g., oncogenes involved in neoplastic transformation. Long noncoding RNA (lncRNA). The human genome also contains a very large number of lncRNAs\u2014at least 30,000, with the total number potentially exceeding coding mRNAs by 10-to 20-fold. lncRNAs modulate gene expression in many ways ("
        },
        {
            "id": "Pathology_Robbins_1475",
            "title": "Pathology_Robbins",
            "content": "Ward PS, Thompson C: Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate, Cancer Cell 21:297\u2013308, 2012. [An account of the molecular pathways of reprogramming of energy metabolism in cancer and the emergence of \u201concometabolites.\u201d] Welti J, Loges S, Dimmeler S, et al: Recent molecular discoveries in angiogenesis and anti-angiogenesis therapies in cancer, J Clin Invest 123:3190\u20133200, 2013. [A discussion of angiogenic mechanisms and successes and challenges of anti-angiogenic therapy in cancer.] White E: The role of autophagy in cancer, J Clin Invest 125:42\u201346, 2016. [A discussion of the diverse possible contributions of autophagy to cancer.] http://ebooksmedicine.net studentconsult.com MendelianDisorders:DiseasesCausedbySingle-GeneDefects Transmission Patterns of Single-Gene Disorders General Features of Chromosomal Diseases Caused by Alterations of Imprinted Regions: Prader-Willi and Angelman Syndromes Molecular Diagnosis of Copy Number Abnormalities"
        },
        {
            "id": "Cell_Biology_Alberts_5623",
            "title": "Cell_Biology_Alberts",
            "content": "Colorectal cancers are common, currently causing nearly 60,000 deaths a year in the United States, or about 10% of total deaths from cancer. Like most cancers, they are not usually diagnosed until late in life (90% occur after the age of 55). However, routine examination of normal adults with a colonoscope (a fiber"
        },
        {
            "id": "Pathology_Robbins_1470",
            "title": "Pathology_Robbins",
            "content": "Molecular analyses are used to determine diagnosis and prognosis, to detect minimal residual disease, and to diagnosepatients with a hereditary predisposition to cancer. Molecular profiling of tumors by RNA expression profiling, DNA sequencing, and DNA copy number arrays are useful inmolecular stratification of otherwise identical tumors or thoseof distinct histogenesis that share a mutation for the purposeof targeted treatment and prognostication. Assays of circulating tumor cells and of DNA shed into blood, stool, sputum, and urine are under development. Artandi SE, DePinho RA: Telomeres and telomerase in cancer, Carcinogenesis 31:9\u201318, 2010. [A review discussing the importance of telomeres and telomerase.] Bai L, Wang S: Targeting apoptosis pathways for new cancer therapeutics, Annual Rev Med 65:139\u2013155, 2014. [A review of apoptosis pathways and therapeutic strategies to activate them in cancer cells.]"
        },
        {
            "id": "Cell_Biology_Alberts_2087",
            "title": "Cell_Biology_Alberts",
            "content": "Finally, we note that some lncRNAs can act only in cis; that is, they affect only the chromosome from which they are transcribed. This readily occurs when the transcribed RNA has not yet been released from RNA polymerases (Figure 7\u201379C). Many lncRNAs, however, diffuse from their site of synthesis and act in trans. Although the best understood lncRNAs work in the nucleus, many are found in the cytosol. The functions\u2014if any\u2014of the great majority of these cytosolic lncRNAs remain undiscovered."
        },
        {
            "id": "Cell_Biology_Alberts_5641",
            "title": "Cell_Biology_Alberts",
            "content": "The steps we have just described are only part of the picture. It is important to emphasize that each case of colorectal cancer is different, with its own detailed combination of mutations, and that even for the mutations that are commonly shared, the sequence of occurrence may vary. The same is true for cancers in general. Advances in molecular biology have recently provided the tools to find out precisely which genes are amplified, deleted, mutated, or misregulated by epigenetic mechanisms in the tumor cells of any given patient. As we discuss in the next section, such information promises to become as important for the diagnosis and treatment of cancer as was the breakthrough of being able to identify microorganisms for the treatment of infectious diseases."
        },
        {
            "id": "Cell_Biology_Alberts_5621",
            "title": "Cell_Biology_Alberts",
            "content": "Colorectal Cancers Evolve Slowly Via a Succession of Visible Changes At the beginning of this chapter, we saw that most cancers develop gradually from a single aberrant cell, progressing from benign to malignant tumors by the accumulation of a number of independent genetic and epigenetic changes. We have discussed what some of these changes are in molecular terms and seen how they contribute to cancerous behavior. We now examine one of the common human cancers more closely, using it to illustrate and enlarge upon some of the general principles and molecular mechanisms we have introduced. We take colorectal cancer as our example."
        },
        {
            "id": "Surgery_Schwartz_8522",
            "title": "Surgery_Schwartz",
            "content": "in colorectal cancer, but this theory remains unproven. DCC mutations are present in more than 70% of colorectal carcinomas and may negatively impact prognosis. SMAD4 functions in the signaling cascade of transforming growth factor beta and beta-catenin (also a down-stream effector of the APC gene). Loss of either of these genes is thought to promote cancer progression.82The Microsatellite Instability Pathway. Many of the remain-ing colorectal carcinomas are thought to arise from mutations in the MSI pathway, which is characterized by errors in mismatch repair during DNA replication. These errors in mismatch repair were first described in Hereditary Nonpolyposis Colon Cancer (HNPCC; Lynch syndrome) Lynch 9, but are now recognized to be present in many sporadic tumors as well. A number of genes have been identified that appear to be crucial for recognizing and repairing DNA replication errors. These mismatch repair genes include MSH2, MLH1, PMS1, PMS2, and MSH6/GTBP. A mutation in one"
        },
        {
            "id": "Cell_Biology_Alberts_5627",
            "title": "Cell_Biology_Alberts",
            "content": "A Few Key Genetic Lesions Are Common to a Large Fraction of Colorectal Cancers What are the mutations that accumulate with time to produce this chain of events? Of those genes so far discovered to be involved in colorectal cancer, three stand out as most frequently mutated: the proto-oncogene K-Ras (a member of the Ras gene family), in about 40% of cases; p53, in about 60% of cases; and the tumor suppressor gene Apc (discussed below), in more than 80% of cases. Others are involved in smaller numbers of colon cancers, and some of these are listed in Table 20\u20131. The role of Apc first came to light through study of certain families showing a rare type of hereditary predisposition to colorectal cancer, called familial"
        },
        {
            "id": "Surgery_Schwartz_2102",
            "title": "Surgery_Schwartz",
            "content": "survivin; increased expression of c-FLIP; mutations or downregulation of proapoptotic Bax, cas-pase 8, APAF1, XAF1, and death receptors CD95, TRAIL-R1, and TRAIL-R2; alterations of the p53 pathway; overexpression of growth factors and growth factor receptors; and activation of the PI3K/Akt survival pathway.20Autophagy in Cancer CellsAutophagy (self-eating) is a major cellular pathway for protein and organelle turnover. The autophagic pathway is a mechanism for the delivery of cellular materials to lysosomes for degra-dation. This process leads to the basal turnover of cell com-ponents and provides energy and macromolecular precursors. This process helps maintain a balance between anabolism and catabolism for normal cell growth and development. Inability to activate autophagy in response to nutrient deprivation, or consti-tutive activation of autophagy in response to stress, can lead to cell death; thus, autophagy is sometimes referred to as a second form of programmed cell death."
        },
        {
            "id": "Pathology_Robbins_24",
            "title": "Pathology_Robbins",
            "content": "(Adapted from Wang KC, Chang HY: Molecular mechanisms of long noncoding RNAs, Mol Cell 43:904, 2011.) a variety of mechanisms ( Fig. 1.4 ). Ongoing studies are exploring the role of lncRNAs in diseases like atherosclerosis and cancer."
        },
        {
            "id": "Cell_Biology_Alberts_5645",
            "title": "Cell_Biology_Alberts",
            "content": "CANCER PREVENTION AND TREATMENT: PRESENT AND FUTURE We can apply the growing understanding of the molecular biology of cancer to sharpen our attack on the disease at three levels: prevention, diagnosis, and treatment. Prevention is always better than cure, and indeed many cancers can be prevented, especially by avoiding smoking. Highly sensitive molecular assays promise new opportunities for earlier and more precise diagnosis, with the aim of detecting primary tumors while they are still small and have not yet metastasized. Cancers caught at these early stages can often be nipped in the bud by surgery or radiotherapy, as we saw for colorectal polyps. Nevertheless, full-blown malignant disease will continue to be common for many years to come, and cancer treatments will continue to be needed."
        },
        {
            "id": "Pathology_Robbins_1290",
            "title": "Pathology_Robbins",
            "content": "Beyond the Warburg effect, there are two other links between metabolism and cancer that are of sufficient importance to merit brief mention, autophagy and an unusual set of oncogenic mutations that lead to the creation of oncometabolites, small molecules that appear to directly contribute to the transformed state."
        },
        {
            "id": "Pathology_Robbins_1486",
            "title": "Pathology_Robbins",
            "content": "It is worth noting that until recently the major focus of gene hunting has been discovery of genes that encode proteins. Recent studies indicate, however, that a very large number of genes do not encode proteins. Instead, the non-encoded products of these genes\u2014so-called \u201cnon-coding RNAs (ncRNAs)\u201d\u2014play important regulatory functions. Although many distinct families of ncRNAs exist, the two most important examples,\u2014small RNA molecules called microRNAs (miRNAs) and long non-coding RNAs (lncRNAs)\u2014are discussed in Chapter 1. With this brief review of the nature of abnormalities that contribute to the pathogenesis of human diseases, we can turn our attention to the three major categories of genetic disorders:"
        },
        {
            "id": "Cell_Biology_Alberts_5524",
            "title": "Cell_Biology_Alberts",
            "content": "In this section, we shall first discuss how cancer-critical genes are identified. We shall then examine their functions and the parts they play in conferring on cancer cells the properties outlined in the first part of the chapter. We shall end the section by discussing colon cancer as an extended example, showing how a succession of changes in cancer-critical genes enables a tumor to evolve from one pattern of bad behavior to another that is worse. The Identification of Gain-of-Function and Loss-of-Function Cancer Mutations has Traditionally Required Different Methods"
        },
        {
            "id": "InternalMed_Harrison_6170",
            "title": "InternalMed_Harrison",
            "content": "Cells, including cancer cells, can also undergo other mechanisms of cell death including autophagy (degradation of proteins and organelles by lysosomal proteases) and necrosis (digestion of cellular components and rupturing of the cell membrane). Necrosis usually occurs in response to external forces resulting in release of cellular components, which leads to inflammation and damage to surrounding tissues. Although necrosis was thought to be unprogrammed, evidence now suggests that at least some aspects may be programmed. The exact role of necrosis in cancer cell death in various settings is still being determined. In addition to its role in cell death, autophagy can serve as a homeostatic mechanism to promote survival for the cell by recycling cellular components to provide necessary energy. The mechanisms that control the balance between enhancing survival versus leading to cell death are still not fully understood. Autophagy appears to play conflicting roles in the development and"
        },
        {
            "id": "Pathology_Robbins_1291",
            "title": "Pathology_Robbins",
            "content": "Autophagy is a state of severe nutrient deficiency in which cells not only arrest their growth, but also cannibalize their own organelles, proteins, and membranes as carbon sources for energy production (Chapter 2). If this adaptation fails, the cells die. Tumor cells often seem to be able to grow under marginal environmental conditions without triggering autophagy, suggesting that the pathways that induce autophagy are deranged. In keeping with this, several genes that promote autophagy are tumor suppressors. Whether autophagy is always bad from the vantage point of the tumor, however, remains a matter of active investigation and debate. For example, under conditions of severe nutrient deprivation, tumor cells may use autophagy to become \u201cdormant,\u201d a state of metabolic hibernation that allows cells to survive hard times for long periods. Such cells are believed to be resistant to therapies that kill actively dividing cells, and could therefore be responsible for therapeutic failures."
        },
        {
            "id": "Cell_Biology_Alberts_2082",
            "title": "Cell_Biology_Alberts",
            "content": "We have already encountered a few lncRNAs, including the RNA in telomerase (see Figure 5\u201333), Xist RNA (see Figure 7\u201352), and an RNA involved in imprinting (see Figure 7\u201349). Other lncRNAs have been implicated in controlling the enzymatic activity of proteins, inactivating transcription regulators, affecting splicing patterns, and blocking translation of certain mRNAs."
        },
        {
            "id": "Cell_Biology_Alberts_5637",
            "title": "Cell_Biology_Alberts",
            "content": "Nevertheless, certain sets of mutations are particularly common in colorectal cancer, and they occur in a characteristic order. Thus, in most cases, mutations inactivating the Apc gene appear to be the first, or at least a very early step, as they are detected at the same high frequency in small benign polyps as in large malignant tumors. Changes that lead to genetic and epigenetic instability are likely also to arise early in tumor progression, since they are needed to drive the later steps. Activating mutations in the K-Ras gene occur later, as they are rare in small polyps but common in larger ones that show disturbances in cell differentiation and histological pattern."
        },
        {
            "id": "Surgery_Schwartz_8521",
            "title": "Surgery_Schwartz",
            "content": "arise from mutations in the LOH pathway. This pathway was first described in patients with FAP in whom mutations of the APC gene were found to be inherited.Another example of LOH occurs in the region of chromo-some 18q. This region has been found to be deleted in up to 70% of colorectal cancers. Two tumor suppressor genes, DCC and SMAD4, are located in this region, and as such, deletion of 18q may result in the loss of one or both of these genes. DCC is a tumor suppressor gene, and loss of both alleles is required for malignant degeneration. The main role of this molecule appears to be in the central nervous system, where it is involved in neural differentiation and axonal migration. This observa-tion has led to the hypothesis that DCC may be involved in differentiation and cellular adhesion in colorectal cancer, but this theory remains unproven. DCC mutations are present in more than 70% of colorectal carcinomas and may negatively impact prognosis. SMAD4 functions in the signaling"
        },
        {
            "id": "Cell_Biology_Alberts_5625",
            "title": "Cell_Biology_Alberts",
            "content": "in which the slowly growing tumor is detectable but has not yet turned malignant. Thus, when people are screened by colonoscopy in their fifties and the polyps are removed through the colonoscope\u2014a quick and easy surgical procedure\u2014the subsequent incidence of colorectal cancer is much lower: according to some studies, less than a quarter of what it would be otherwise."
        },
        {
            "id": "Cell_Biology_Alberts_5635",
            "title": "Cell_Biology_Alberts",
            "content": "Thus, the genetic instability found in many colorectal cancers can be acquired in at least two ways. The majority of the cancers display a form of chromosomal instability that leads to visibly altered chromosomes, whereas in the others the instability occurs on a much smaller scale and reflects a defect in DNA mismatch repair. Indeed, many carcinomas show either chromosomal instability or defective mismatch repair\u2014but rarely both. These findings clearly demonstrate that genetic instability is not an accidental by-product of malignant behavior but a contributory cause\u2014and that cancer cells can acquire this instability in multiple ways. The Steps of Tumor Progression Can Often Be Correlated with Specific Mutations"
        },
        {
            "id": "Cell_Biology_Alberts_5644",
            "title": "Cell_Biology_Alberts",
            "content": "We can often correlate the steps of tumor progression with mutations that activate specific oncogenes and inactivate specific tumor suppressor genes, with colon cancer providing a good example. But different combinations of mutations and epigenetic changes are found in different types of cancer, and even in different patients with the same type of cancer, reflecting the random way in which these inherited changes arise. Nevertheless, many of the same changes are encountered repeatedly, suggesting that there are a limited number of ways to breach our defenses against cancer. Figure 20\u201336 Suggested typical sequence of genetic changes underlying the development of a colorectal carcinoma. This oversimplified diagram provides a general idea of the way mutation and tumor development are related. But many other mutations are generally involved, and different colon cancers can progress through different sequences of mutations (and/or epigenetic changes)."
        },
        {
            "id": "Cell_Biology_Alberts_5654",
            "title": "Cell_Biology_Alberts",
            "content": "in some cases, have declined significantly (Figure 20\u201339). Survival rates, moreover, have improved. Thirty years ago, less than 50% of patients lived more than five years from the time of diagnosis; now, more than two-thirds do so."
        },
        {
            "id": "Cell_Biology_Alberts_2089",
            "title": "Cell_Biology_Alberts",
            "content": "noncoding RNAs (lncRNAs) has recently been discovered. Although the function of most of these RNAs is unknown, some serve as RNA scaffolds to bring specific proteins and how is the final rate of transcription of a gene specified by the hundreds of proteins that assemble on its control regions? will we ever be able to predict this rate from inspection of the DnA sequences of control regions?"
        }
    ],
    "scores": [
        0.03450459862826086,
        0.03347992434697203,
        0.03201569131818873,
        0.027626692878986458,
        0.026999688764394646,
        0.02636737921071835,
        0.026083262088954687,
        0.025602368043422134,
        0.024857627868428697,
        0.022843446065428825,
        0.022309917565319005,
        0.022295543374783434,
        0.02217852323115481,
        0.021765530925013682,
        0.02168859649122807,
        0.02124600005741054,
        0.021038035260712698,
        0.019704911667637354,
        0.01677805625174046,
        0.01655982905982906,
        0.016516816516816517,
        0.016405517610820944,
        0.016226514255682563,
        0.01620224435758416,
        0.01601510169285105,
        0.015840978593272173,
        0.015822388993120703,
        0.015705838876570587,
        0.01546451914098973,
        0.015460621912234816,
        0.015385525770755665,
        0.015173218738394608
    ]
}